In an Era of ctDNA, Is Metabolomics the New Kid on the Block?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35140120.
- Also identified by DOI 10.1158/1078-0432.CCR-21-4180.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mass action drives the serum homeostasis of metabolites. Recent developments in biofluid metabolomics suggest the potential to harness these changes using small volumes of blood to diagnose, monitor, and risk stratify patients with cancer. This current study may represent a complementary technology to circulating tumor DNA detection. See related article by Larkin et al., p. 1651.
Medical subject headings
- Circulating Tumor DNA
- Neoplasms